Calibrium Overview

  • Founded
  • 2012

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Calibrium General Information


Developer of drugs for treatment of Diabetes. The company is developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 11711 North Meridian Street
  • Suite 300
  • Carmel, IN 46032
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calibrium Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 27-Aug-2015 00.000 Completed Generating Revenue
1. Convertible Debt 20-Dec-2013 00.000 00.000 Completed Generating Revenue
To view Calibrium’s complete valuation and funding history, request access »

Calibrium Executive Team (6)

Name Title Board Seat Contact Info
Jaswant Gidda Ph.D Vice President of Preclinical Development
You’re viewing 1 of 6 executive team members. Get the full list »

Calibrium Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
BioCrossroads Venture Capital Minority 000 0000 000000 0
Frazier Healthcare Partners PE/Buyout Minority 000 0000 000000 0
To view Calibrium’s complete investors history, request access »